Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41415-025-8306-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Clinical Validity and Reliability of Artificial Intelligence-Enabled Diagnostic Tools in Neuropsychiatric Disorders.
Cureus
October 2024
Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Neuropsychiatric disorders (NPDs) pose a substantial burden on the healthcare system. The major challenge in diagnosing NPDs is the subjective assessment by the physician which can lead to inaccurate and delayed diagnosis. Recent studies have depicted that the integration of artificial intelligence (AI) in neuropsychiatry could potentially revolutionize the field by precisely diagnosing complex neurological and mental health disorders in a timely fashion and providing individualized management strategies.
View Article and Find Full Text PDFTrials and tribulations of cell therapy for heart failure: an update on ongoing trials.
Nat Rev Cardiol
November 2024
Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, Université de Paris, PARCC, INSERM, Paris, France.
Article Synopsis
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.
Curr Oncol
August 2024
Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Pancreatic adenocarcinoma represents one of the most challenging malignancies to treat, with dismal survival rates despite advances in therapeutic modalities. Immunotherapy, particularly vaccines, has emerged as a promising strategy to harness the body's immune system in combating this aggressive cancer. This abstract reviews the trials and tribulations encountered in the development of vaccines targeting pancreatic adenocarcinoma.
View Article and Find Full Text PDFAdvances in pharmacotherapy for sickle cell disease: what is the current state of play?
Expert Opin Pharmacother
July 2024
Lifespan Comprehensive Sickle Cell Center, University of Alabama Birmingham, Birmingham, AL, USA.
Introduction: Despite over 100 years of neglect and insufficient funding, sickle cell disease has risen to the top of the discussions due to the recent approval of two new genetic therapies. Prior to these approvals, there were only four prior approved medications for sickle cell disease in spite of being the most common inherited blood disorder. The advent and expense of these new genetic therapies have finally brought the trials and tribulations associated with SCD including the suffering and early mortality of affected individuals to the much-needed limelight.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!